Hurun Research Institute officially released the "2024 Hurun Brand List" on April 16, selecting the most valuable brands in China. Among them, Yiling Pharmaceutical has successfully ranked among the "top three most valuable brands in the region" with its outstanding brand influence and market performance, and has been ranked among the top 10 medical and health brand values, once again demonstrating its leading position in the pharmaceutical and health industry.

Picture 1.png

As a top 100 brand value enterprise in China, Yiling Pharmaceutical has always adhered to the innovative development strategy of "market leader, technology-driven", and has built a five-in-one operating model of "theory-clinical-scientific research-industry-teaching", forming an industrial structure covering three major business segments of patented traditional Chinese medicine, chemical and biochemical drugs, and health industries. Yiling Pharmaceutical has made outstanding achievements in the field of scientific and technological innovation, and has won 6 national science and technology awards, among which "Construction of Traditional Chinese Medicine's Craft Theory and Guiding the Prevention and Control of Microvascular Lesions" won the first prize of National Science and Technology Progress in 2019, which is the only first prize in the field of life sciences of the year.

In the past two years, the national key R&D program "Research on the Intervention Chain of Cardiovascular Events in the Biology Theory Guidance System" has made a major breakthrough. The relevant results were selected as landmark cases of the 2024 World Traditional Medicine Conference and won the first prize of Science and Technology of the Chinese Society of Integrated Traditional Chinese and Western Medicine. It is particularly worth mentioning that the research results related to the treatment of acute myocardial infarction of Tongxinluo Capsules in the sub-topic of this project have been listed in the Journal of the American Medical Association (JAMA), becoming a milestone in the internationalization of traditional Chinese medicine. In addition, patented products such as Lianhua Qingwen Capsules and Tongxinluo Capsules produced by Yiling Pharmaceutical are not only widely recognized in the domestic market, but have also been approved for marketing in more than 50 countries and regions including Canada and Singapore, becoming a "business card" for traditional Chinese medicine to go global.

It is reported that since its first release in 2005, the Hurun brand list has tracked the evolution of Chinese brands for 19 consecutive years, becoming an important yardstick for measuring the brand value of Chinese companies. This list provides authoritative reference for the public and investors by comprehensively evaluating the brand's market value, consumer awareness and industry influence.

Hurun, chairman and chief researcher of Hurun Group, said that the Hurun brand list shows the rise of Chinese brands and the improvement of national recognition. With its excellent quality, cultural value and consumer experience, domestic trendy products have won the trust of consumers, reflecting the enhancement of China's manufacturing innovation.

[Editor in charge: Sun Hui]